Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib vs antihistamines for cholinergic urticaria and symptomatic dermographism (retrospective cohort)
ChiCTR2600117340Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tofacitinib in chronic urticaria (CU) (2 arms), sponsored by Southern Medical University Dermatology Hospital. Primary endpoint: Change in Urticaria Control Test (UCT) relative to baseline. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on ChiCTR2600117340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117340.